Intellectual Property India Publishes Patent Application for 'Amorphous Solid Dispersion Formulation Of Nebivolol Hydrochloride With Peg 6000 And/Or Poloxamer 407 For Enhanced Dissolution And Bioavailability' Filed by Dr. Divya Ajmeera; Dr. Shanthipriya Ajmera; Prof. Sarangapani Manda; and Dr. Rajanna Ajumeera

MUMBAI, India, April 17 -- Intellectual Property India has published a patent application (202641043561 A) filed by Dr. Divya Ajmeera; Dr. Shanthipriya Ajmera; Prof. Sarangapani Manda; and Dr. Rajanna Ajumeera, Karimnagar, Telangana, on April 6, for 'amorphous solid dispersion formulation of nebivolol hydrochloride with peg 6000 and/or poloxamer 407 for enhanced dissolution and bioavailability.'

Inventor(s) include Dr. Divya Ajmeera; Dr. Shanthipriya Ajmera; Prof. Sarangapani Manda; and Dr. Rajanna Ajumeera.

The application for the patent was published on April 17, under issue no. 16/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to a pharmaceutical solid dispersion formulation comprising Nebivolol Hydrochloride dispersed within a hydrophilic polymer carrier selected from polyethylene glycol 6000 (PEG 6000), Poloxamer 407, or combinations thereof, for improving the solubility and dissolution characteristics of the drug. Nebivolol Hydrochloride, a poorly water-soluble active pharmaceutical ingredient, is incorporated into the polymeric carrier matrix in a substantially amorphous form, thereby reducing crystallinity and enhancing wettability and dissolution behaviour. The solid dispersion may be prepared using manufacturing techniques such as melt fusion, solvent evaporation, spray drying, or hot-melt extrusion, enabling reproducible and scalable pharmaceutical production. Analytical characterization techniques including X-ray diffraction (XRD) and differential scanning calorimetry (DSC) confirm the amorphous dispersion of the drug within the polymer matrix. The resulting formulation demonstrates significantly enhanced dissolution performance compared with conventional crystalline Nebivolol Hydrochloride formulations, thereby improving the potential oral bioavailability and therapeutic effectiveness of the drug. The solid dispersion may further be incorporated into oral dosage forms such as tablets or capsules for administration to patients."

Disclaimer: Curated by HT Syndication.